Join our daily newsletter At The Bell to receive exclusive market insights
- Incannex Healthcare (IHL) engages Eurofins Scientific to manufacture IHL’s ReneCann product for skin diseases
- Eurofins will produce the topical treatment to be used in clinical trials to confirm the safety and therapeutic effect of the drug on certain dermatological conditions
- Incannex says the trial data will be used in the chemistry and manufacturing control modules of future regulatory packages with the US Food and Drug Administration
- This product is Incannex’s first to use cannabigerol — a minor cannabinoid — and IHL says expansion in this space provides opportunities to explore new therapeutic areas
- Shares in Incannex are up 2.08 per cent to 24.5 cents at 11:40 am AEDT
Incannex Healthcare (IHL) has engaged contract development and manufacturing organisation (CDMO) Eurofins Scientific to manufacture IHL’s ReneCann product for skin diseases.
ReneCann is a topical cannabinoid formulation for the treatment of dermatological conditions caused by disorders of the immune system, including eczema.
Eurofins will produce the treatment to be used in clinical trials to confirm the safety and therapeutic effect of ReneCann in vitiligo, psoriasis, and atopic dermatitis.
The trial data on the quality and stability of ReneCann will be used in the chemistry and manufacturing control modules of future regulatory packages with the US FDA.
Incannex Chief Scientific Officer Mark Bleackley said the production of ReneCann added a new route of cannabinoid delivery to the company’s portfolio, opening the possibility for direct application to affected areas in dermatological conditions.
“ReneCann is also Incannex’s first product to incorporate CBG, a minor cannabinoid,” Dr Bleackley said.
“Expansion into minor cannabinoids provides us the opportunity to explore different activity profiles of this diverse family of molecules across a range of new therapeutic areas.”
A previous version of ReneCann was used in an in-human proof of concept study with dosing over a six-week period.
The study showed a reduction in disease scores in patients with each of the target skin diseases.
Shares in Incannex were up 2.08 per cent to 24.5 cents at 11:40 am AEDT.
